This comes with a rider that Dr Reddy’s will initially be able to import a limited number of Sputnik V doses from Russia, and there would be no additional vaccines at the country’s disposal till mid-year.
MUMBAI: There would be a need for an additional 1.2 billion doses (assuming two jabs per person) from May, with the government opening up vaccination for everyone above 18 years. This is because an estimated 44% or around 600 million of the country’s population falls in the 18-45 years age group.
Assuming the ramped up capacity by June, three vaccine firms Serum Institute (100 m doses per month of Covishield), Bharat Biotech (10 m per month of Covaxin), and Dr Reddy’s (around 4 m doses per month of Sputnik V) will together be able to throw up only 115 million jabs per month, just about 10% of the total demand.
Sputnik V to be $300 million boost to Dr Reddy s
The company has got permission from the Drug Controller General of India (DCGI) to import the vaccine. Reddy s is also going to tap domestically contract manufactured vaccines as and when companies are allowed to start commercial manufacturing in India
PB Jayakumar | April 14, 2021 | Updated 17:35 IST
Dr Reddy s to market and distribute 250 doses of Sputnik V
Dr Reddy s Laboratories, which has exclusive marketing and distribution rights for the first 250 million doses of Russia s Sputnik V vaccines in India, may get potential upside revenues of $300 million from the contract, estimates an analyst report.
The government s Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recently recommended Russian Direct Investment Fund (RDIF) s Sputnik V vaccine for Emergency Use Authorisation (EUA) in India, subject to satisfactory immunogenicity data submission.
Sputnik V to be $300 million boost to Dr Reddy s- Business News businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Divi’s Lab, one of best performing large-cap stocks, sees wave of bullish calls
Premium
(REUTERS)
Ronojoy Mazumdar
, Bloomberg
Overall in absolute terms, analysts’ average 12-month target price for Divi’s stock has risen about ₹134 in the past four weeks
Share Via
Some analysts are turning even more bullish on India’s best-performing large-cap stock in 2020.
In just about two weeks, at least four brokerages have raised their price targets on Divi’s Laboratories Ltd., one of the top producers of active pharmaceutical ingredients, with Jefferies India Pvt.’s estimate which targets a 21% gain over the next 12 months from current levels being the most bullish in data compiled by Bloomberg.
India’s best-performing stock is seeing a wave of optimistic calls
Indian API exporters have been increasing their share of the U.S. market at the expense of Europe and China-based rivals
(HT PRINT)Premium
Some analysts are turning even more bullish on India’s best-performing large-cap stock in 2020.
Share Via Some analysts are turning even more bullish on India’s best-performing large-cap stock in 2020.
In just about two weeks, at least four brokerages have raised their price targets on the shares of Divi’s Laboratories Ltd. one of the top producers of active pharmaceutical ingredients with Jefferies India Pvt.’s estimate of an almost 20% gain over the next 12 months being the most bullish in data compiled by Bloomberg.